Student of Data Science and Analytics at USP/Esalq and a doctoral candidate in Molecular Oncology at Barretos Cancer Hospital, where he investigates the role of metabolism in the aggressiveness and resistance of clear cell renal cell carcinoma. In the Master's program in Molecular Oncology, also conducted at the same hospital, he studied the effects of the metabolic inhibitor 3-bromopyruvate on vemurafenib-resistant melanoma cells. With a background in Biochemistry from the Federal University of São João del-Rei (UFSJ), during three and a half years as an Undergraduate Researcher, he participated in projects exploring the antineoplastic and wound-healing effects of natural extracts, both in vivo and in vitro. He also holds technical qualifications in Industrial Automation and Civil Engineering. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Clear-cell renal cell carcinoma (ccRCC), the most lethal type of neoplasia among the urologic malignancies, accounts for 75-85% of all kidney cancers. In clinical practice, even in the era of immunotherapy, sunitinib is often used as the first line of treatment against this neoplasia. However, despite presenting an initial response, about 70% of patients treated with this drug develop res…
The major part of the solid tumors reprograms its energetic metabolism, depending for the most part on the glycolytic pathway for energy obtention, even in the presence of oxygen - a phenomenon known as the Warburg effect. In this context, the monocarboxylates transporters (MCTs), specifically the MCT1 and MCT2 isoforms, perform an essential role, contributing to the continuous flux of gl…
Introduction: Clear cell renal cell carcinoma (ccRCC) accounts for 75-85% of renal malignancies, being the most lethal subtype of urological cancers. Despite the presence of immunotherapy in clinical practice, sunitinib is frequently used for the treatment of ccRCC, and is even adopted by the Brazilian public health system (SUS) for metastatic cases. However, approximately 70% of patients…
| 2 / 2 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 3 / 3 | All Scholarships |
| Associated processes | |
CV Lattes
ORCID